The stock of Sarepta Therapeutics Inc (NASDAQ: SRPT) has increased by 6.09 when compared to last closing price of 117.12.Despite this, the company has seen a gain of 5.39% in its stock price over the last five trading days. Business Wire reported 2024-04-24 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sare.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
The stock has a 36-month beta value of 0.97. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 6 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SRPT is 88.26M, and at present, short sellers hold a 5.21% of that float. On April 25, 2024, the average trading volume of SRPT was 818.53K shares.
SRPT’s Market Performance
The stock of Sarepta Therapeutics Inc (SRPT) has seen a 5.39% increase in the past week, with a -2.88% drop in the past month, and a 3.35% gain in the past quarter. The volatility ratio for the week is 3.65%, and the volatility levels for the past 30 days are at 2.76% for SRPT. The simple moving average for the past 20 days is 0.65% for SRPT’s stock, with a 11.57% simple moving average for the past 200 days.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with BMO Capital Markets repeating the rating for SRPT by listing it as a “Outperform.” The predicted price for SRPT in the upcoming period, according to BMO Capital Markets is $170 based on the research report published on January 31, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $113. The rating they have provided for SRPT stocks is “Buy” according to the report published on December 13th, 2023.
Deutsche Bank gave a rating of “Buy” to SRPT, setting the target price at $109 in the report published on December 12th of the previous year.
SRPT Trading at -1.33% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.29% of loss for the given period.
Volatility was left at 2.76%, however, over the last 30 days, the volatility rate increased by 3.65%, as shares sank -3.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.41% lower at present.
During the last 5 trading sessions, SRPT rose by +5.39%, which changed the moving average for the period of 200-days by +13.47% in comparison to the 20-day moving average, which settled at $123.24. In addition, Sarepta Therapeutics Inc saw 28.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Boor Kathryn Jean, who sale 761 shares at the price of $122.93 back on Mar 11 ’24. After this action, Boor Kathryn Jean now owns 7,516 shares of Sarepta Therapeutics Inc, valued at $93,550 using the latest closing price.
Wigzell Hans Lennart Rudolf, the Director of Sarepta Therapeutics Inc, sale 15,000 shares at $123.25 during a trade that took place back on Mar 08 ’24, which means that Wigzell Hans Lennart Rudolf is holding 22,840 shares at $1,848,795 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.88 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at -0.43. The total capital return value is set at -0.1. Equity return is now at value -86.15, with -16.77 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.4.
Currently, EBITDA for the company is -267.82 million with net debt to EBITDA at -4.3. When we switch over and look at the enterprise to sales, we see a ratio of 10.16. The receivables turnover for the company is 2.83for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.95.
Conclusion
To sum up, Sarepta Therapeutics Inc (SRPT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
